Latest Period
Q4 2025
- Info
- Insider Trading
- Financials
- Holders
Security Snapshot
Olema Pharmaceuticals, Inc. - Common Stock, par value $0.0001 per share (OLMA) Institutional Ownership
CUSIP: 68062P106
13F Institutional Holders and Ownership History from Q4 2020 to Q1 2026
Institutions Reporting
198
Shares (Excl. Options)
90,695,275
Price
$25.00
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place.
- Type / Class
- Equity / Common Stock, par value $0.0001 per share
- Symbol
- OLMA on Nasdaq
- Shares outstanding
- 87,489,196
- Price per share
- $14.91
- All holders as of 31 Dec 2025
- Q4 2025
- Total 13F shares
- 90,695,275
- Total reported value
- $2,267,572,776
- % of total 13F portfolios
- 0.01%
- Share change
- +21,306,933
- Value change
- +$591,383,435
- Number of holders
- 198
- Price from insider filings
- $14.91
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors
Quick Takeaways
- OLMA - Olema Pharmaceuticals, Inc. - Common Stock, par value $0.0001 per share is tracked under CUSIP 68062P106.
- 198 institutions reported positions in Q4 2025.
- 7 significant owners is listed from Schedule 13D/13G reporting.
What Changed
- Holder count moved from 198 to 10 between Q4 2025 and Q1 2026.
- Reported value moved from $2,267,572,776 to $1,496,374.
Why This Matters
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Source Evidence
Source: SEC Form 13F
Open SEC Evidence
Latest holder context comes from 198 institutions filings for Q4 2025.
Investment Quick Answers
What is CUSIP 68062P106?
CUSIP 68062P106 identifies OLMA - Olema Pharmaceuticals, Inc. - Common Stock, par value $0.0001 per share in SEC 13F datasets.
Where can I see the latest institutional holders?
Review the Q4 2025 holders report and the ownership history table below.
Next ownership checks
Use the next link that matches the question you still need to answer about this security.
- Latest 13F filings when you want to inspect fresh institutional portfolio moves.
- Latest Schedule 13D/13G reports when you need large-owner changes outside the 13F cycle.
- All institutional ownership pages to compare this security with other holder-history pages.
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 68062P106:
Significant Owners of Olema Pharmaceuticals, Inc. - Common Stock, par value $0.0001 per share (OLMA) based on Schedule 13D/G filings
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| FMR LLC | 12% | +103% | $250,051,474 | +$124,423,925 | 9,998,060 | +99% | FMR LLC | 27 Feb 2026 |
| Bain Capital Life Sciences Opportunities IV, L.P. | 10% | 0% | $244,963,774 | +$47,926,339 | 8,508,641 | +24% | Bain Capital Life Sciences Opportunities IV, L.P. | 31 Dec 2025 |
| Paradigm Biocapital Advisors LP | 10% | $37,443,949 | 7,429,355 | Paradigm BioCapital Advisors LP | 31 Dec 2024 | |||
| JANUS HENDERSON GROUP PLC | 8.4% | +64% | $193,186,485 | +$89,949,893 | 6,710,194 | +87% | JANUS HENDERSON GROUP PLC | 31 Dec 2025 |
| Invus Global Management, LLC | 5.1% | $108,693,078 | 4,461,949 | Raymond Debbane | 16 Mar 2026 | |||
| Logos Global Management LP | 4.7% | $16,172,730 | 3,208,875 | Logos Global Management LP | 18 Mar 2025 | |||
| Point72 Asset Management, L.P. | 2.3% | $7,781,412 | 1,543,931 | Point72 Asset Management, L.P. | 31 Mar 2025 |
As of 31 Dec 2025, 198 institutional investors reported holding 90,695,275 shares of Olema Pharmaceuticals, Inc. - Common Stock, par value $0.0001 per share (OLMA). This represents 104% of the company’s total 87,489,196 outstanding shares.
Top 25 Institutional Shareholders
The largest institutional shareholders of Olema Pharmaceuticals, Inc. - Common Stock, par value $0.0001 per share (OLMA) together control 84% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| Bain Capital Life Sciences Investors, LLC | 9.7% | 8,508,641 | +24% | 16% | $212,716,025 |
| Paradigm Biocapital Advisors LP | 8.6% | 7,544,172 | +11% | 5% | $188,604,300 |
| JANUS HENDERSON GROUP PLC | 7.7% | 6,710,194 | +87% | 0.08% | $167,901,108 |
| BlackRock, Inc. | 6.4% | 5,563,260 | +18% | 0% | $139,081,500 |
| BVF INC/IL | 6.1% | 5,295,893 | 0% | 4.5% | $132,397,325 |
| FMR LLC | 5.7% | 5,023,092 | +16973% | 0.01% | $125,577,309 |
| VANGUARD GROUP INC | 4.1% | 3,561,355 | +11% | 0% | $89,033,875 |
| Siren, L.L.C. | 3.8% | 3,300,700 | 2.5% | $82,517,500 | |
| Logos Global Management LP | 3.7% | 3,208,875 | 0% | 5.3% | $80,221,875 |
| Cormorant Asset Management, LP | 3.1% | 2,750,000 | 3.9% | $68,750,000 | |
| RA CAPITAL MANAGEMENT, L.P. | 3% | 2,600,000 | 0.67% | $65,000,000 | |
| FRANKLIN RESOURCES INC | 2.8% | 2,476,665 | -18% | 0.02% | $61,916,625 |
| LIGHTSPEED MANAGEMENT COMPANY, L.L.C. | 2.2% | 1,930,894 | 0% | 3.5% | $48,272,350 |
| STATE STREET CORP | 2.2% | 1,884,399 | +72% | 0% | $47,109,975 |
| Vestal Point Capital, LP | 1.9% | 1,650,000 | 1.5% | $41,250,000 | |
| Woodline Partners LP | 1.7% | 1,481,930 | -33% | 0.14% | $37,048,250 |
| Polar Capital Holdings Plc | 1.6% | 1,380,450 | 0.16% | $34,511,250 | |
| GEODE CAPITAL MANAGEMENT, LLC | 1.4% | 1,257,441 | -1.5% | 0% | $31,441,734 |
| Defilade Capital Management, L.P. | 1.4% | 1,234,634 | 0% | 4.2% | $30,865,850 |
| CITADEL ADVISORS LLC | 1.4% | 1,200,307 | -3% | 0.02% | $30,007,675 |
| PRICE T ROWE ASSOCIATES INC /MD/ | 1.3% | 1,096,035 | +3349% | 0% | $27,402,000 |
| SAMLYN CAPITAL, LLC | 1.2% | 1,069,543 | 0.43% | $26,738,575 | |
| JENNISON ASSOCIATES LLC | 1.1% | 963,997 | 0.01% | $24,099,925 | |
| DIMENSIONAL FUND ADVISORS LP | 1.1% | 958,644 | -9.9% | 0.01% | $23,966,274 |
| KINGDON CAPITAL MANAGEMENT, L.L.C. | 1.1% | 953,600 | +12% | 3.6% | $23,840,000 |
Institutional Holders of Olema Pharmaceuticals, Inc. - Common Stock, par value $0.0001 per share (OLMA) across Reporting Periods
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q1 | 100,358 | $1,496,374 | -$1,212,777 | $14.91 | 10 |
| 2025 Q4 | 90,695,275 | $2,267,572,776 | +$591,383,435 | $25.00 | 198 |
| 2025 Q3 | 68,238,531 | $668,036,044 | -$3,229,086 | $9.79 | 124 |
| 2025 Q2 | 70,511,948 | $300,429,144 | +$22,565,282 | $4.26 | 120 |
| 2025 Q1 | 65,888,228 | $247,927,417 | -$30,654,965 | $3.76 | 131 |
| 2024 Q4 | 71,278,859 | $415,382,388 | +$48,509,843 | $5.83 | 154 |
| 2024 Q3 | 58,658,581 | $700,332,942 | +$12,555,131 | $11.94 | 129 |
| 2024 Q2 | 57,896,539 | $626,445,097 | +$18,080,243 | $10.82 | 127 |
| 2024 Q1 | 56,110,675 | $635,162,151 | +$37,635,929 | $11.32 | 125 |
| 2023 Q4 | 51,618,204 | $717,066,039 | +$56,526,765 | $14.03 | 113 |
| 2023 Q3 | 47,322,813 | $584,436,985 | +$135,063,720 | $12.35 | 97 |
| 2023 Q2 | 36,408,086 | $328,764,561 | +$43,216,272 | $9.03 | 86 |
| 2023 Q1 | 33,447,196 | $116,103,891 | +$1,469,913 | $3.47 | 65 |
| 2022 Q4 | 33,334,567 | $81,640,055 | -$481,138 | $2.45 | 66 |
| 2022 Q3 | 33,359,693 | $92,063,140 | -$4,143,577 | $2.76 | 67 |
| 2022 Q2 | 34,202,982 | $139,234,855 | -$8,391,103 | $4.07 | 70 |
| 2022 Q1 | 36,374,849 | $155,206,361 | -$17,958,891 | $4.26 | 86 |
| 2021 Q4 | 38,428,075 | $359,510,482 | -$41,441,250 | $9.36 | 94 |
| 2021 Q3 | 36,741,334 | $1,012,524,920 | -$19,680,898 | $27.56 | 75 |
| 2021 Q2 | 37,428,321 | $1,047,268,923 | +$59,576,299 | $27.98 | 68 |
| 2021 Q1 | 35,240,926 | $1,158,274,244 | -$1,710,105 | $33.18 | 73 |
| 2020 Q4 | 35,073,865 | $1,657,230,008 | +$1,657,206,010 | $48.08 | 56 |